Pharmstandard Competitors and Similar CompaniesClear all

Pharmstandard's competitors and similar companies include Agios Pharmaceuticals, Turning Point Therapeutics, Farmabios and Recordati.

	Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.	Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.	Farmabios Farmabios is a company that manufactures non-sterile and sterile steroids.	Recordati Recordati Industria Chimica e Farmaceutica is a company that specializes in the manufacturing and marketing of pharmaceutical products.
Founding Date	Founding Date 2003	Founding Date 2008	Founding Date 2013	Founding Date 1961	Founding Date 1926
Type	Type Subsidiary	Type Public	Type Subsidiary	Type Subsidiary	Type Public
Tags	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma
Locations	Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Tomsk, RU Ufa, RU	Locations Cambridge, US HQ	Locations San Diego, US HQ	Locations Gropello Cairoli, IT HQ	Locations Milano, IT HQ Campoverde, IT
Employees	Employees 1,56135% increase	Employees 53611% increase	Employees 25024% increase	Employees 200	Employees 4,450
Valuation ($)	Valuation ($) N/A	Valuation ($) 2.4 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 11.8 b
Financial
Revenue (est.)	Revenue (est.) ₽142.9b (FY, 2023)	Revenue (est.) $26.8m (FY, 2023)	Revenue (est.) $30.8m (FY, 2021)	Revenue (est.) €127.4m (Y, 2024)	Revenue (est.) €2.1b (FY, 2023)
Cost of goods	Cost of goods ₽109.3b (FY, 2023)	Cost of goods $2.9m (FY, 2023)	Cost of goods N/A	Cost of goods N/A	Cost of goods €459.3m (FY, 2023)
Gross profit	Gross profit ₽33.6b (FY, 2023)	Gross profit $23.9m (FY, 2023)	Gross profit N/A	Gross profit N/A	Gross profit €1.6b (FY, 2023)
Net income	Net income ₽23.3b (FY, 2023)	Net income ($352.1m) (FY, 2023)	Net income ($236.6m) (FY, 2021)	Net income €23.8m (Y, 2024)	Net income €389.2m (FY, 2023)